1. Home
  2. CELC vs LFST Comparison

CELC vs LFST Comparison

Compare CELC & LFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$53.29

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo LifeStance Health Group Inc.

LFST

LifeStance Health Group Inc.

N/A

Current Price

$13.83

Market Cap

4.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CELC
LFST
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.8B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
CELC
LFST
Price
$53.29
$13.83
Analyst Decision
Strong Buy
Buy
Analyst Count
13
11
Target Price
★ $150.85
$16.80
AVG Volume (30 Days)
920.9K
★ 6.2M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,424,285,000.00
Revenue This Year
N/A
$22.65
Revenue Next Year
$1,921.71
$13.62
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 13.85
52 Week Low
$53.54
$6.21
52 Week High
$151.02
$15.66

Technical Indicators

Market Signals
Indicator
CELC
LFST
Relative Strength Index (RSI) 30.06 52.01
Support Level N/A $11.73
Resistance Level $72.76 $14.15
Average True Range (ATR) 4.24 0.82
MACD -1.03 -0.10
Stochastic Oscillator 0.16 20.99

Price Performance

Historical Comparison
CELC
LFST

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

About LFST LifeStance Health Group Inc.

LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.

Share on Social Networks: